Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...
CRISPR Therapeutics (CRSP) reported new preclinical data from its novel SyNTase gene editing platform for the treatment of Alpha-1 Antitrypsin ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...
In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...
Late-breaking data at the ESC Congress showcased the success of STX-1200, a novel CasXE-based therapy for durably lowering Lp(a). STX-1200 achieved unprecedented potency and specificity, with >90% ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback